×
About 1,182 results

ALLMedicine™ Targeted Cancer Therapy Center

Research & Reviews  585 results

Genetically Engineered Bacterial Protein Nanoparticles for Targeted Cancer Therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802776
International Journal of Nanomedicine; Yang H, Jiang F et. al.

Jan 15th, 2021 - Cancer treatment still faces big challenges in the clinic, which is raising concerns over the world. In this study, we report the novel strategy of combing bacteriotherapy with high-intensity focused ultrasound (HIFU) therapy for more efficient br...

Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanos...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797289
Drug Design, Development and Therapy; Rudzińska M, Daglioglu C et. al.

Jan 14th, 2021 - In cancer treatments, many natural and synthetic products have been examined; among them, protease inhibitors are promising candidates for anti-cancer agents. Since dysregulated proteolytic activities can contribute to tumor development and metast...

Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
https://doi.org/10.1111/bcp.14723
British Journal of Clinical Pharmacology; Schneider JJ, Galettis P et. al.

Jan 2nd, 2021 - Despite advances in targeted cancer therapy, the fluoropyrimidines 5-fluorouracil (5FU) and capecitabine continue to play an important role in oncology. Historically, dosing of these drugs has been based on body surface area. This approach has bee...

Nivolumab-induced plaque morphea in a malign melanoma patient.
https://doi.org/10.1111/jocd.13914
Journal of Cosmetic Dermatology REFERENCES; Acar A, Oraloglu G et. al.

Dec 28th, 2020 - Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melan...

Tweak to Treat: Reprograming Bacteria for Cancer Treatment.
https://doi.org/10.1016/j.trecan.2020.11.004
Trends in Cancer; Sieow BF, Wun KS et. al.

Dec 11th, 2020 - Recent advancements in cancer biology, microbiology, and bioengineering have spurred the development of engineered live biotherapeutics for targeted cancer therapy. In particular, natural tumor-targeting and probiotic bacteria have been engineered...

see more →

Clinicaltrials.gov  593 results

Genetically Engineered Bacterial Protein Nanoparticles for Targeted Cancer Therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802776
International Journal of Nanomedicine; Yang H, Jiang F et. al.

Jan 15th, 2021 - Cancer treatment still faces big challenges in the clinic, which is raising concerns over the world. In this study, we report the novel strategy of combing bacteriotherapy with high-intensity focused ultrasound (HIFU) therapy for more efficient br...

Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanos...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797289
Drug Design, Development and Therapy; Rudzińska M, Daglioglu C et. al.

Jan 14th, 2021 - In cancer treatments, many natural and synthetic products have been examined; among them, protease inhibitors are promising candidates for anti-cancer agents. Since dysregulated proteolytic activities can contribute to tumor development and metast...

Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
https://doi.org/10.1111/bcp.14723
British Journal of Clinical Pharmacology; Schneider JJ, Galettis P et. al.

Jan 2nd, 2021 - Despite advances in targeted cancer therapy, the fluoropyrimidines 5-fluorouracil (5FU) and capecitabine continue to play an important role in oncology. Historically, dosing of these drugs has been based on body surface area. This approach has bee...

Nivolumab-induced plaque morphea in a malign melanoma patient.
https://doi.org/10.1111/jocd.13914
Journal of Cosmetic Dermatology REFERENCES; Acar A, Oraloglu G et. al.

Dec 28th, 2020 - Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melan...

Tweak to Treat: Reprograming Bacteria for Cancer Treatment.
https://doi.org/10.1016/j.trecan.2020.11.004
Trends in Cancer; Sieow BF, Wun KS et. al.

Dec 11th, 2020 - Recent advancements in cancer biology, microbiology, and bioengineering have spurred the development of engineered live biotherapeutics for targeted cancer therapy. In particular, natural tumor-targeting and probiotic bacteria have been engineered...

see more →

News  4 results

Managing dermatologic changes of targeted cancer therapy
https://www.mdedge.com/familymedicine/article/204934/oncology/managing-dermatologic-changes-targeted-cancer-therapy/page/0/6?channel=203
MDedge Family Medicine;

Aug 1st, 2019 - Does rash correlate with cancer treatment efficacy? Despite troubling dermatologic effects of cancer therapies, a retrospective analysis of several clinical trials has revealed another side to this coin: namely, the appearance, and the severity, o.

New Scale Grades Mutations, Optimizing Targeted Cancer Therapy
https://www.medscape.com/viewarticle/901258

Aug 27th, 2018 - A new scale for tumor DNA mutations that aims to simplify and standardize the choice of targeted therapies has been introduced by the European Society for Medical Oncology (ESMO). Known as ESCAT (ESMO Scale for Clinical Actionability of Molecular ...

Pruritus prophylaxis appropriate for targeted cancer therapies
https://www.mdedge.com/hematology-oncology/article/102308/patient-survivor-care/pruritus-prophylaxis-appropriate-targeted
Ted Bosworth

Aug 30th, 2015 - NEW YORK – Due to the frequency with which patients develop pruritus while on a targeted cancer therapy, prophylaxis should be strongly considered for at least some of the drugs, such as epidermal growth factor–receptor (EGFR) inhibitors, accordin.

Targeted Therapies Emerge for Nonmelanoma Skin Cancer
https://www.mdedge.com/dermatology/article/11440/melanoma/targeted-therapies-emerge-nonmelanoma-skin-cancer
Bruce Jancin

MADRID - Targeted therapy - the glamour area of cancer research in recent years - has arrived at the doorstep of nonmelanoma skin cancer in a big way. "There are at least 24 open trials of targeted therapies for nonmelanoma skin cancer listed now.

see more →